NCT06926673 - Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 23, 2021

Primary Completion Date

May 2, 2024

Study Completion Date

May 2, 2024

Conditions

Neoplasms

Interventions

DRUG

Dostarlimab

Dostarlimab will be administered

DRUG

Belrestotug.

Belrestotug will be administered

DRUG

Nelistotug

Nelistotug will be administered.

Trial Locations (15)

20133

GSK Investigational Site, Milan

22927

GSK Investigational Site, Großhansdorf

28034

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

33076

GSK Investigational Site, Bordeaux

37203

GSK Investigational SIte, Nashville

47014

GSK Investigational Site, Meldola FC

53100

GSK Investigational Site, Siena

75018

GSK Investigational Site, Paris

75248

GSK Investigational Site, Paris

94805

GSK Investigational Site, Villejuif

T6G 1Z2

GSK Investigational Site, Edmonton

L6R 3J7

GSK Investigational Site, Brampton

M5G 2M9

GSK Investigational Site, Toronto

08035

GSK Investigational Site, Barcelona